TECHNOLOGY

The explosion of emerging cell and gene therapy programs that modify and reprogram a patient’s own cells has created immense opportunity for treating intractable diseases. However, high treatment costs, a complex supply chain, and limited payer budgets and treatment reimbursement have created an unsustainable manufacturing and treatment delivery model that is forcing the biopharmaceutical industry to reconsider its approach.

​

Lupagen’s closed-loop, patient-connected, bedside point-of care system provides a better alternative to harnessing a patient’s cells, while keeping costs in line with conventional biologics therapies.